Clinical Trial Update: Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC). [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Immunopheresis alone or in combination with paclitaxel or atezolizumab in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Immunopheresis
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Immunicom Inc | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN